{"id":3365,"date":"2026-04-02T09:07:07","date_gmt":"2026-04-02T16:07:07","guid":{"rendered":"https:\/\/boomersbrokeamerica.com\/glp-1-drug-pricing-ozempic-wegovy-mounjaro-cost-unaffordable\/"},"modified":"2026-04-02T09:07:07","modified_gmt":"2026-04-02T16:07:07","slug":"glp-1-drug-pricing-ozempic-wegovy-mounjaro-cost-unaffordable","status":"publish","type":"post","link":"https:\/\/boomersbrokeamerica.com\/ro\/glp-1-drug-pricing-ozempic-wegovy-mounjaro-cost-unaffordable\/","title":{"rendered":"GLP-1 Drug Pricing: How Ozempic, Wegovy, Mounjaro Cost $1,400\/Month \u2014 and Who Can&#8217;t Afford Them"},"content":{"rendered":"<p>GLP-1 drugs cost $1,100\u2013$1,400 per month. Novo Nordisk cut prices 35\u201350% in February 2026 after pressure from Congress and the Trump administration. Medicare negotiated $245\/month. But for 22 million uninsured Americans and those on specialty insurance tiers? They&#8217;re paying full freight. These drugs work. They reduce cardiovascular death risk. They control obesity and diabetes. But for Millennials and Gen Z, a medication that could extend life is literally unaffordable. Billionaires take Ozempic for vanity. Working people ration doses or don&#8217;t fill the prescription at all.<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1429\" src=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-glp1-drugs-expensive-pricing-crisis-scaled.jpg\" alt=\"GLP-1 drugs expensive pricing\" class=\"wp-image-3359\" srcset=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-glp1-drugs-expensive-pricing-crisis-scaled.jpg 2560w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-glp1-drugs-expensive-pricing-crisis-300x167.jpg 300w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-glp1-drugs-expensive-pricing-crisis-1024x572.jpg 1024w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-glp1-drugs-expensive-pricing-crisis-768x429.jpg 768w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-glp1-drugs-expensive-pricing-crisis-1536x857.jpg 1536w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-glp1-drugs-expensive-pricing-crisis-2048x1143.jpg 2048w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-glp1-drugs-expensive-pricing-crisis-18x10.jpg 18w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/><figcaption>$1,100\u2013$1,400\/month before cuts. Novo reduced 35\u201350% in Feb 2026. Still unaffordable for uninsured.<\/figcaption><\/figure>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\"><nav><ul><li><a href=\"#why-are-glp-1-drugs-so-expensive\">Why Are GLP-1 Drugs So Expensive?<\/a><\/li><li><a href=\"#who-pays-the-1400-full-price\">Who Pays the $1,400 Full Price?<\/a><\/li><li><a href=\"#the-feb-2026-price-cut\">The Feb 2026 Price Cut<\/a><\/li><li><a href=\"#congress-investigates-april-2-2026\">Congress Investigates (April 2, 2026)<\/a><\/li><li><a href=\"#the-generational-divide-boomers-pay-245-millennials-pay-1400\">The Generational Divide<\/a><\/li><li><a href=\"#why-stopping-glp-1s-is-dangerous\">Why Stopping GLP-1s Is Dangerous<\/a><\/li><li><a href=\"#counter-argument-pharma-needs-high-prices-for-rd\">Counter-Argument<\/a><\/li><li><a href=\"#faq-glp-1-pricing\">FAQ: GLP-1 Pricing<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<p><strong>Key Takeaways<\/strong><\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>List price: $1,100\u2013$1,400\/month<\/strong> (Ozempic, Wegovy, Mounjaro) before Feb 2026<\/li>\n<li><strong>Novo Nordisk cut 35\u201350%<\/strong> in February 2026, but list prices still high<\/li>\n<li><strong>Medicare negotiated $245\/month<\/strong> (Trump administration, Nov 2025)<\/li>\n<li><strong>Uninsured\/specialty tier: still $500\u2013$1,400\/month<\/strong><\/li>\n<li><strong>Direct-to-consumer: $350\/month<\/strong> (down from $500)<\/li>\n<li><strong>Congress investigating Apr 2, 2026<\/strong> \u2014 cost, safety, access<\/li>\n<li><strong>Stopping GLP-1s erases cardiovascular benefits<\/strong> \u2014 lifelong affordability critical<\/li>\n<li><strong>Generational divide:<\/strong> Boomers $245. Millennials $1,400.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-are-glp-1-drugs-so-expensive\">Why Are GLP-1 Drugs So Expensive?<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1429\" src=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-pharmaceutical-pricing-profits-scaled.jpg\" alt=\"Drug pricing profit margin\" class=\"wp-image-3360\" srcset=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-pharmaceutical-pricing-profits-scaled.jpg 2560w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-pharmaceutical-pricing-profits-300x167.jpg 300w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-pharmaceutical-pricing-profits-1024x572.jpg 1024w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-pharmaceutical-pricing-profits-768x429.jpg 768w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-pharmaceutical-pricing-profits-1536x857.jpg 1536w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-pharmaceutical-pricing-profits-2048x1143.jpg 2048w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-pharmaceutical-pricing-profits-18x10.jpg 18w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/><figcaption>Manufacturing cost: $5\u2013$10. List price: $1,100\u2013$1,400. Pure profit: 110\u2013280\u00d7.<\/figcaption><\/figure>\n\n\n\n<p>Novo Nordisk, Eli Lilly, and Pfizer control the GLP-1 market. Prices before Feb 2026: Ozempic ($950\u2013$1,100\/month), Wegovy ($1,100\u2013$1,300), Mounjaro ($1,200\u2013$1,349), Zepbound ($1,400+). Manufacturing cost: $5\u2013$10 per dose. List price: 110\u2013280\u00d7 manufacturing cost. Why so high?<\/p>\n<ul><li><strong>R&#038;D markup<\/strong> \u2014 drug costs $5\u201310 billion to develop<\/li>\n<li><strong>Market monopoly<\/strong> \u2014 only three companies make GLP-1s; zero competition<\/li>\n<li><strong>Insurance leverage loss<\/strong> \u2014 demand was so high insurers raised formulary coverage despite high prices<\/li>\n<li><strong>Specialty pharmacy markup<\/strong> \u2014 Novo owns specialty pharmacies, adds distribution margin<\/li>\n<li><strong>Direct-to-consumer demand<\/strong> \u2014 celebrities\/wealthy buying Ozempic off-label created scarcity<\/li>\n<\/ul>\n<p>Result: GLP-1s became the most profitable drug class in the world. Until Congress complained.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"who-pays-the-1400-full-price\">Who Pays the $1,400 Full Price?<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1429\" src=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-generational-healthcare-inequality-scaled.jpg\" alt=\"Generational inequality healthcare insurance\" class=\"wp-image-3361\" srcset=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-generational-healthcare-inequality-scaled.jpg 2560w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-generational-healthcare-inequality-300x167.jpg 300w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-generational-healthcare-inequality-1024x572.jpg 1024w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-generational-healthcare-inequality-768x429.jpg 768w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-generational-healthcare-inequality-1536x857.jpg 1536w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-generational-healthcare-inequality-2048x1143.jpg 2048w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-generational-healthcare-inequality-18x10.jpg 18w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/><figcaption>Medicare: $245\/month. Commercial copay: $150\u2013$500. Uninsured: $1,100+. Age determines access.<\/figcaption><\/figure>\n\n\n\n<p><strong>Medicare (65+):<\/strong> Negotiated $245\/month (out-of-pocket $0\u2013$50). Why? Seniors are a voting bloc. Congress gave Medicare statutory power to negotiate drug prices.<\/p>\n<p><strong>Commercial Insurance (younger workers):<\/strong> $150\u2013$300\/month in-network copay (requires prior authorization). Specialty tier: $300\u2013$500. Insurance companies place GLP-1s on specialty tiers to drive high copays.<\/p>\n<p><strong>Uninsured (22 million Americans):<\/strong> List price $1,100\u2013$1,400\/month. Zero negotiating power. Pay full freight or go without.<\/p>\n<p><strong>Self-Insured (gig workers, freelancers):<\/strong> $1,100\u2013$1,400\/month without negotiation. Manufacturer savings programs sometimes reduce to $50\u2013$300, but eligibility is complex.<\/p>\n<p><strong>Direct-to-Consumer (TrumpRx, Roman, GoodRx, Mark Cuban Cost Plus):<\/strong> $350\/month for starter doses. Quality\/oversight varies. No insurance required but no doctor oversight either.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-feb-2026-price-cut\">The Feb 2026 Price Cut: Why Novo Finally Blinked<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1429\" src=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-novo-nordisk-price-cut-2026-scaled.jpg\" alt=\"Novo Nordisk price cut 2026\" class=\"wp-image-3362\" srcset=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-novo-nordisk-price-cut-2026-scaled.jpg 2560w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-novo-nordisk-price-cut-2026-300x167.jpg 300w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-novo-nordisk-price-cut-2026-1024x572.jpg 1024w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-novo-nordisk-price-cut-2026-768x429.jpg 768w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-novo-nordisk-price-cut-2026-1536x857.jpg 1536w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-novo-nordisk-price-cut-2026-2048x1143.jpg 2048w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-novo-nordisk-price-cut-2026-18x10.jpg 18w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/><figcaption>Feb 24, 2026: Novo cuts 35\u201350%. But insurers keep copays high. Corporate PR win. Patient win partial.<\/figcaption><\/figure>\n\n\n\n<p>On Feb 24, 2026, Novo Nordisk cut list prices 35\u201350%. Why the sudden generosity?<\/p>\n<ul><li><strong>Political pressure:<\/strong> Trump threatened regulation. Congress investigation loomed.<\/li>\n<li><strong>Business pressure:<\/strong> GLP-1 shortage easing. Competitors (Eli Lilly, Pfizer) faced same pressure. Generic semaglutide coming 2025\u20132027.<\/li>\n<li><strong>Price war starting:<\/strong> Manufacturers realized cutting prices is better than losing market to generics.<\/li>\n<\/ul>\n<p>New list prices post-cut: ~$650\u2013$700\/month. But here&#8217;s the catch: Insurance copays stayed the same. Only uninsured patients benefit via manufacturer savings programs \u2014 maybe $50\u2013$300 off. Still $400\u2013$1,000+\/month.<\/p>\n<p><strong>Truth:<\/strong> The cuts are PR. Insurance copays didn&#8217;t move. Medicare was already at $245. Uninsured patients saw minimal benefit.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"congress-investigates-april-2-2026\">Congress Investigates (April 2, 2026)<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1429\" src=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-congress-glp1-investigation-scaled.jpg\" alt=\"Congress investigating GLP-1 legislation\" class=\"wp-image-3363\" srcset=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-congress-glp1-investigation-scaled.jpg 2560w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-congress-glp1-investigation-300x167.jpg 300w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-congress-glp1-investigation-1024x572.jpg 1024w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-congress-glp1-investigation-768x429.jpg 768w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-congress-glp1-investigation-1536x857.jpg 1536w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-congress-glp1-investigation-2048x1143.jpg 2048w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-congress-glp1-investigation-18x10.jpg 18w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/><figcaption>Apr 2, 2026: Congress probes cost, safety, prior authorization. Legislation expected Q3 2026.<\/figcaption><\/figure>\n\n\n\n<p>On Apr 2, 2026 (today), Congress took a &#8220;fresh look at GLP-1 legislation on cost, safety.&#8221; They&#8217;re investigating:<\/p>\n<ol><li><strong>Pricing transparency:<\/strong> Require manufacturers to disclose pricing rationale<\/li>\n<li><strong>Prior authorization limits:<\/strong> Ban insurance companies from requiring prior auth (forces patients to wait weeks for approval)<\/li>\n<li><strong>Medicare negotiation expansion:<\/strong> Let Medicare negotiate GLP-1s at launch (not after $100M+ annual sales)<\/li>\n<li><strong>Safety review:<\/strong> Investigate pancreatitis, gastroparesis (stomach paralysis) reports<\/li>\n<li><strong>Compounding pharmacy regulation:<\/strong> Regulate online GLP-1 dispensing (TrumpRx, Roman) for safety<\/li>\n<\/ol>\n<p>Expect legislation by Q3 2026 capping copays at $50\/month, mandating generic development, and limiting prior authorization. Manufacturers will lobby hard against it.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-generational-divide-boomers-pay-245-millennials-pay-1400\">The Generational Divide: Boomers Pay $245. Millennials Pay $1,400.<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1429\" src=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-boomer-millennial-drug-price-divide-scaled.jpg\" alt=\"Boomer millennial drug price divide\" class=\"wp-image-3364\" srcset=\"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-boomer-millennial-drug-price-divide-scaled.jpg 2560w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-boomer-millennial-drug-price-divide-300x167.jpg 300w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-boomer-millennial-drug-price-divide-1024x572.jpg 1024w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-boomer-millennial-drug-price-divide-768x429.jpg 768w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-boomer-millennial-drug-price-divide-1536x857.jpg 1536w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-boomer-millennial-drug-price-divide-2048x1143.jpg 2048w, https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-boomer-millennial-drug-price-divide-18x10.jpg 18w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/><figcaption>Boomers negotiate. Millennials suffer. $245\/month vs. $1,400 for the same lifesaving drug.<\/figcaption><\/figure>\n\n\n\n<p><strong>Boomer (70+ on Medicare):<\/strong> $245\/month. Why? Seniors are a voting bloc. Congress prioritized Medicare drug negotiation.<\/p>\n<p><strong>Millennial (35\u201345, employer insurance):<\/strong> $150\u2013$500\/month, depending on tier placement. Good health plan? $150. Mediocre? $500.<\/p>\n<p><strong>Gen Z (25\u201335, no insurance or high-deductible plan):<\/strong> $1,100\u2013$1,400\/month. Cannot afford lifesaving drug.<\/p>\n<p><strong>The injustice:<\/strong> GLP-1s reduce cardiovascular death significantly. Younger people with chronic disease (diabetes, obesity) need lifelong treatment. At $1,400\/month, that&#8217;s $16,800\/year or $453,600 lifetime. Boomers got Medicare negotiation. Millennials\/Gen Z got neither. Generational wealth inequality + healthcare system inequality = young people literally rationing life-saving drugs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-stopping-glp-1s-is-dangerous\">Why Stopping GLP-1s Is Dangerous (And Why Affordability Matters)<\/h2>\n\n\n\n<p>In March 2026, Washington University researchers found that stopping GLP-1s, even briefly, erases cardiovascular benefits. Patients who stopped semaglutide or tirzepatide experienced immediate risk elevation for heart attack, stroke, and death.<\/p>\n<p><strong>Implication:<\/strong> GLP-1s aren&#8217;t one-off weight-loss treatment. They&#8217;re lifelong medications. Missing a month due to cost can have fatal consequences.<\/p>\n<p>For uninsured and underinsured patients, this means: Can&#8217;t afford this month&#8217;s dose \u2192 skip it \u2192 cardiovascular benefits erase \u2192 higher risk of heart attack\/stroke \u2192 system says it&#8217;s &#8220;their fault&#8221; for not having insurance.<\/p>\n<p><strong>Truth:<\/strong> System failed to price medication affordably. System created unaffordable medication. System blames patients when they ration.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"counter-argument-pharma-needs-high-prices-for-rd\">Counter-Argument: &#8220;Pharma Needs High Prices for R&#038;D&#8221;<\/h2>\n\n\n\n<p>Pharmaceutical companies argue: Real R&#038;D cost is $5\u201315 billion per drug. Only high prices recoup. Risk is real \u2014 90% of candidates fail; profitable drugs fund failed research. Competition drives innovation. Price controls stifle it. U.S. high prices subsidize lower-price markets.<\/p>\n<p><strong>Valid points:<\/strong> R&#038;D is expensive. Pharma did need profit to fund GLP-1 development.<\/p>\n<p><strong>But:<\/strong> Once R&#038;D is sunk, high prices serve pure profit. Novo Nordisk cut 35\u201350% without cutting innovation. Patent monopolies are government-granted; government can regulate them. Real solution: faster generic entry, cap copays at $50, fund R&#038;D via public\/nonprofit research.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"faq-glp-1-pricing\">FAQ: GLP-1 Pricing<\/h2>\n\n\n\n<p><strong>Q: Can I get GLP-1 cheaper without insurance?<\/strong> A: TrumpRx (~$350\/month), Mark Cuban Cost Plus Drugs, GoodRx, Roman offer $200\u2013$500\/month. Starter doses only. Quality\/oversight varies. Talk to doctor.<\/p>\n<p><strong>Q: Will my insurance cover GLP-1?<\/strong> A: Most cover if diagnosed with type 2 diabetes or obesity (BMI >30). Weight loss (vanity) typically not covered. Prior authorization required (2\u20134 week wait). Ask your doctor to file appeals if denied.<\/p>\n<p><strong>Q: Is Medicare price ($245) permanent?<\/strong> A: Yes, for 2026. Subject to annual CMS review. Likely to remain low given political pressure and generics coming 2025\u20132027.<\/p>\n<p><strong>Q: When will generics be available?<\/strong> A: Semaglutide (Ozempic\/Wegovy) generic 2025\u20132026. Tirzepatide (Mounjaro\/Zepbound) generic 2028\u20132030. Generic prices will be $50\u2013$150\/month.<\/p>\n<p><strong>Q: Can I stop taking GLP-1s?<\/strong> A: No, if you want cardiovascular benefits. WashU 2026 study shows stopping even briefly erases heart protection. Lifelong drug for most.<\/p>\n<p><strong>Q: Do GLP-1s have side effects?<\/strong> A: Yes. GI side effects (nausea, constipation) affect ~30%. Rare but serious: pancreatitis, gastroparesis. Congress investigating safety Apr 2, 2026. Always discuss with doctor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sources-and-methodology\">Sources and Methodology<\/h2>\n\n\n\n<p><strong>GLP-1 Pricing &#038; Costs (Feb\u2013Apr 2026):<\/strong> Novo Nordisk press release (Feb 24, 2026), CNBC (Feb 24, 2026), GLP-1 Journal\/GLP-1 Health (Jan 2026), AARP\/Harvard Gazette\/STAT News (2026).<\/p>\n<p><strong>Medicare Negotiation:<\/strong> White House fact sheet (Nov 2025), KFF, Healthcare.gov.<\/p>\n<p><strong>Generational Impact:<\/strong> Business Insider (Apr 2024), Harvard Gazette (Feb 2026), Washington University Medicine (Mar 2026).<\/p>\n<p><strong>Congress Investigation:<\/strong> Bloomberg Government News (Apr 2, 2026), Senate Health Committee.<\/p>","protected":false},"excerpt":{"rendered":"<p>GLP-1 drugs cost $1,100\u2013$1,400 per month. Novo Nordisk cut prices 35\u201350% in February 2026 after pressure from Congress and the Trump administration. Medicare negotiated $245\/month. But for 22 million uninsured Americans and those on specialty insurance tiers? They&#8217;re paying full freight. These drugs work. They reduce cardiovascular death risk. They control obesity and diabetes. But [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":3359,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_gspb_post_css":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-3365","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"blocksy_meta":[],"jetpack_featured_media_url":"https:\/\/boomersbrokeamerica.com\/wp-content\/uploads\/2026\/04\/bba-glp1-drugs-expensive-pricing-crisis-scaled.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/boomersbrokeamerica.com\/ro\/wp-json\/wp\/v2\/posts\/3365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/boomersbrokeamerica.com\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/boomersbrokeamerica.com\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/boomersbrokeamerica.com\/ro\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/boomersbrokeamerica.com\/ro\/wp-json\/wp\/v2\/comments?post=3365"}],"version-history":[{"count":0,"href":"https:\/\/boomersbrokeamerica.com\/ro\/wp-json\/wp\/v2\/posts\/3365\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/boomersbrokeamerica.com\/ro\/wp-json\/wp\/v2\/media\/3359"}],"wp:attachment":[{"href":"https:\/\/boomersbrokeamerica.com\/ro\/wp-json\/wp\/v2\/media?parent=3365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/boomersbrokeamerica.com\/ro\/wp-json\/wp\/v2\/categories?post=3365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/boomersbrokeamerica.com\/ro\/wp-json\/wp\/v2\/tags?post=3365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}